Semaglutide is a long-acting GLP-1 receptor agonist that has been the subject of one of the largest peptide clinical trial programmes published to date. This article summarises the UK regulatory position and the published research literature in a research-only framing. It does not describe how to obtain, prescribe, dose or use semaglutide in people, and nothing in this article should be read as medical or pharmacy advice.
UK Regulatory Status
In the UK, semaglutide is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) under three licensed brands manufactured by Novo Nordisk: Ozempic (subcutaneous, type 2 diabetes), Wegovy (subcutaneous, weight management) and Rybelsus (oral, type 2 diabetes). Each brand has a separate MHRA marketing authorisation, Summary of Product Characteristics (SmPC), and indication. Access to these licensed medicines is solely a matter for a registered prescriber and a licensed pharmacy, and falls outside the scope of this site.
Research-grade semaglutide reference material, of the kind referenced in laboratory and preclinical literature, is supplied as an unlicensed research chemical. It is not a medicine, is not approved by the MHRA for human use, and is not interchangeable with the licensed brands above.
Mechanism of Action (Published Research)
Semaglutide is a 31-amino-acid analogue of human GLP-1 with substitutions and a C18 fatty acid side chain that extend its plasma half-life to approximately one week. In published mechanistic and clinical studies it has been characterised as a selective agonist at the GLP-1 receptor, with reported effects on:
- Glucose-dependent insulin secretion from pancreatic beta cells (in vitro and clinical pharmacology data)
- Suppression of glucagon release under hyperglycaemic conditions
- Delayed gastric emptying measured by paracetamol absorption studies
- Central nervous system signalling at hypothalamic GLP-1 receptors associated with food intake regulation in animal models
Reported Clinical Trial Endpoints
The published STEP (weight management) and SUSTAIN (type 2 diabetes) trial programmes have reported on, among other endpoints:
- Change in HbA1c from baseline in adults with type 2 diabetes
- Change in body weight from baseline in defined adult populations
- Composite cardiovascular outcomes in SUSTAIN-6 (Marso et al., NEJM, 2016)
- Adverse event profile, dominated by gastrointestinal events during titration
These endpoints describe the licensed medicine administered under trial protocols and supervision. They are not predictive of any outcome from research reference material and are reported here purely as published literature.
Oral Semaglutide (Research Interest)
The licensed oral formulation (Rybelsus and, in the US market, an oral Wegovy formulation launched in January 2026) is co-formulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC), and is one of the few oral peptide products to reach approval. Researchers interested in oral peptide delivery often reference these formulations in absorption-enhancer literature, separately from any prescribing context. See our analysis of the oral GLP-1 research landscape.
Adverse Events Reported in Published Trials
Gastrointestinal events (nausea, vomiting, diarrhoea, constipation) dominate the reported safety profile in the STEP and SUSTAIN programmes, with reported incidence figures broadly aligned with other GLP-1 receptor agonists. Less common serious events reported include pancreatitis, biliary disease, and a boxed warning relating to rodent thyroid C-cell tumour findings. Lean body mass changes during weight loss have been reported in published trials and are summarised in our lean mass outcomes article.
Comparative Research Context
Semaglutide is frequently referenced alongside the dual GIP/GLP-1 agonist tirzepatide and the triple GIP/GLP-1/glucagon agonist retatrutide in incretin pharmacology literature. Researchers comparing these molecules typically refer to differences in receptor selectivity, half-life and reported trial endpoints rather than head-to-head therapeutic positioning. See our tirzepatide vs semaglutide research summary and retatrutide vs tirzepatide notes.
Key References
- Wilding, J.P.H. et al. (2021). "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine, 384(11), 989-1002.
- Davies, M. et al. (2021). "Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 2)." The Lancet, 397(10278), 971-984.
- Marso, S.P. et al. (2016). "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." NEJM, 375(19), 1834-1844.
- NICE Technology Appraisal TA875. "Semaglutide for managing overweight and obesity." March 2023.